We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alligator Bioscience Ab | LSE:0RK9 | London | Ordinary Share | SE0000767188 | ALLIGATOR BIOSCIENCE ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Noncomml Resh Organizations | 61.9M | -248.59M | -1.1221 | -20.50 | 5.1B |
From May 2019 to May 2024
LUND, Sweden, March 18, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been published. The Annual Report is attached as a PDF and is available on the company's website, https://alligatorbioscience.se/en/investors/financial-reports/
For further information, please contact:
Per Norlén, CEO
E-mail: per.norlen@alligatorbioscience.com
Phone: +46 46 540 82 00
Marie Svensson, CFO
E-mail: marie.svensson@alligatorbioscience.com
Phone: +46 46 540 82 03
The information was submitted for publication, through the agency of the contact person set out above, at 4:30 p.m. CET on March 18, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-PrimeTM. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-publishes-annual-report-for-2020,c3309387
The following files are available for download:
https://mb.cision.com/Main/12681/3309387/1389090.pdf | Alligator Bioscience Annual Report 2020 |
Copyright 2021 PR Newswire
1 Year Alligator Bioscience Ab Chart |
1 Month Alligator Bioscience Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
